# **Clinical Genomics Data Infrastructure and ClinVar**

U. Geigenmüller<sup>1</sup>, D. Maglott<sup>2</sup>, S. Aradhya<sup>3</sup>, S. Bale<sup>3</sup>, P.R. Billings<sup>4</sup>, C. Braastad<sup>5</sup>, M. Eisenberg<sup>6</sup>, M.J. Ferber<sup>7</sup>, K. Fuentes Fajardo<sup>8</sup>, M. Hegde<sup>9</sup>, B. Kattman<sup>2</sup>, S.F. Kingsmore<sup>10</sup>, I.S. Kohane<sup>11</sup>, D.H. Ledbetter<sup>12</sup>, K. Lee<sup>11</sup>, E. Lyon<sup>13</sup>, C. Lese Martin<sup>9</sup>, N.A. Miller<sup>10</sup>, J. Ostell<sup>2</sup>, J. Paschall<sup>2</sup>, H.L. Rehm<sup>14</sup>, G.R. Riley<sup>2</sup>, C.J. Saunders<sup>10</sup>, S.T. Sherry<sup>2</sup>, E.D. Trautman<sup>6</sup>, V. Zvereff<sup>6</sup>, D.M. Margulies<sup>15</sup> 1) Channing Laboratory, Brigham and Women's Hospital, Boston, MA; 2) National Center for Biotechnology Information, NLM, OIH, Bethesda, MD; 3) GeneDx, Gaithersburg, MD; 4) LIFE Technologies, Carlsbad, CA; 5) Athena Diagnostics, Worcester, MA; 6) LabCorp/CMBP, Raleigh, NC; 7) Mayo Clinic, Rochester, MN; 8) NIH/NHGRI/OCD/Undiagnosed Diseases Program, Bethesda, MD; 9) Department of Human Genetics, Emory University School of Medicine, Atlanta, GA; 10) Children's Mercy Hospital, Kansas City, MO; 11) Center for Biomedical Informatics, Harvard Medical School, Boston, MA; 12) Geisinger Health System, Danville, PA; 13) University of Utah Pathology Department/ARUP Laboratories, Salt Lake City, UT; 14) Harvard Medical School, Boston, MA; 15) Correlagen Diagnostics, Waltham, MA.

### **Problem Statement**

Adoption of large-scale sequencing in molecular diagnostics is limited by difficulty of assessing the clinical significance of detected variants.

#### Limited accessibility of variant observation data

- Primary data are fragmented across publications, locus-specific databases, and proprietary databases and thus hard to find or completely inaccessible.
- Lack of standardization of data structures hinders meta analysis of available data.

#### Inconsistent variant interpretations

- Varying sets of public data and local primary data used to derive clinical significance of the same variant
- Varying assessment methods used to derive clinical significance from primary data

## **Project Goal**

To develop a centralized, freely accessible, clinical-grade database that ...

#### Increases data accessibility and consistency of use

Access to all relevant data from both public and private sources

#### Promotes consistent data use

- Defined data structure enables meta-analysis
- Database checks on accuracy and internal consistency of variant description

#### Enables scalable variant analysis

- All data on a given variant aggregated in one place
- Data mining by manual community effort and automated text mining

#### Variant interpretation not scalable

Data searches and interpretations largely manual and prohibitively labor intensive

#### Community experience and expertise not shared

No mechanism for sharing interpretive decisions widely across laboratories

### **ClinVar Database**

- ClinVar: created and maintained by NCBI (<u>http://www.ncbi.nlm.nih.gov/clinvar</u> see Poster Clinical genetics resources at NCBI: ClinVar and ISCA support evidencebased interpretation of human variation)
- Controlled vocabulary used for description of variants and associated phenotypes (Table 1).

Given an identifier, ClinVar will calculate other identifiers as applicable and check submission for internal consistency

#### Table 1: Variant and phenotype descriptors (by submission)

| Variant<br>description | Chromosomal co-ordinates: NCBI identifiers preferred, CCDS, UCSC, or ENSEMBL acceptable |
|------------------------|---|
|                        | Coding co-ordinates: HGVS identifiers <sup>1</sup>                                      |
|                        | Variant type: Sequence Ontology identifiers <sup>2</sup>                                |
| Associated             | SNOMED CT preferred, UMLS, MeSH, HPO, OMIM, ICD-9, ICD-10, free text acceptable         |

Data stored and retrievable in computable format

#### **Provides confidence measure for clinical interpretation**

- Multiple clinical interpretations stored for each variant, with each interpretation tagged by submitter and algorithm used
  - $\rightarrow$  Divergent interpretations indicate uncertainty
- Clinical interpretations classified by curation level


#### Promotes currency of clinical interpretation

- Alert issued if new data or new interpretations for a variant become available
  - **Revised interpretation can be issued**  $\rightarrow$

Enables development and calibration of interpretive algorithms

## Variant Data Flow

#### Integration of ClinVar with other databases and tools



#### pnenotypes

**Experimental system** 

• Aim is to capture as much data as possible and allow users to make independent judgments on the quality of assertions (Table 2)

| Table 2: Data quality (by data source) |  |  |
|--|--|--|
|  | Detection platform   |  |
| Variant detection method               | PHRED score for the variant call and/or<br>metric of technology-specific false positive rate |  |
| Phenotype assertion method             | Symptoms preferred, test indication acceptable   |  |
| Type of experimental system            | Type of model (animal, cell based, in-vitro)   |  |

Observational data will be categorized to allow meta-analysis and use in automated rules-based scoring algorithms (Table 3).

#### Table 3: Observational data (by data source)

| Unrelated unaffected<br>individuals | # individuals tested                                       |
|-------------------------------------|--|
|                                     | Ethnicity of individuals tested                            |
| AND                                 | Age group of individuals tested                            |
| Unrelated affected individuals      | # variant occurrences                                      |
|                                     | # affected with variant                                    |
|                                     | # related affected without variant                         |
| Affected femilies                   | # variant occurrences in affected                          |
| Affected families                   | # de-novo variant occurrences in affected                  |
|                                     | # observed transmissions of variant allele from het parent |

### Status

- 36 labs that have agreed to contribute sequence-level data
- 20,000 variants loaded
- Position papers about policies for participation, sustainability model, ClinVar data elements, standards, and technical methods available on

#### # observed transmissions of variant allele from het parent

# related unaffected with variant (zygosity consistent with mode of inheritance), by age group

Effect size

Clinical assertions will be categorized as uncurated or curated by registered submitter, by expert-panel, or by practice guideline

| Table 4: Clinical assertion (by submission) |                                  |  |  |  |
|---|----------------------------------|--|--|--|
|   | Variant classification category  |  |  |  |
| <b>Clinical assertion</b>                   | Method of variant classification |  |  |  |
|   | Curation level                   |  |  |  |
|   |                                  |  |  |  |

http://www.ncbi.nlm.nih.gov/clinvar/community/

Mailing List Address: <u>clinvar@ncbi.nlm.nih.gov</u>

### References

- 1. Human Genome Variation Society: Nomenclature for the description of sequence variants <a href="http://www.hgvs.org/mutnomen/">http://www.hgvs.org/mutnomen/</a>
- 2. The Sequence Ontology Project. <u>http://www.sequenceontology.org/</u>